Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAILFREE-C: Hepatitis C Elimination in Prison
NCT02768961Phase 4Completed
- Sponsor
- IDIVAL
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ledipasvir in hepatitis C (HCV), sponsored by IDIVAL. Primary endpoints: Prevalence of chronic hepatitis C at 12 months and Sustained Virological Response at 12 weeks. Started May 2016; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02768961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768961.